scholarly journals Pulmonary functional MRI : Detecting the structure–function pathologies that drive asthma symptoms and quality of life

Respirology ◽  
2022 ◽  
Author(s):  
Harkiran K. Kooner ◽  
Marrissa J. McIntosh ◽  
Vedanth Desaigoudar ◽  
Jonathan H. Rayment ◽  
Rachel L. Eddy ◽  
...  
Epidemiology ◽  
2004 ◽  
Vol 15 (4) ◽  
pp. S136-S137
Author(s):  
Jane Clougherty ◽  
Jonathan I. Levy ◽  
John D. Spengler ◽  
Brent Coull ◽  
H Patricia Hynes

2003 ◽  
Vol 178 (9) ◽  
pp. 437-441 ◽  
Author(s):  
Robert D Goldney ◽  
Richard Ruffin ◽  
David H Wilson ◽  
Laura J Fisher

2018 ◽  
Vol 9 (2) ◽  
pp. 74-77
Author(s):  
Mesbahul Karim Ruble ◽  
AKM Rafiqul Bari ◽  
Amar Biswas ◽  
Md Khairul Anam ◽  
Mahbub E Khuda ◽  
...  

Objective: The aims and objective of this study to observe the improvement in Nocturnal Asthma symptoms and Quality of Life (QoL) with administration of once daily sustained release theophylline preparation.Background: Nocturnal symptoms are a common part of the asthma. Nocturnal asthma is defined by a drop in forced expiratory volume in 1 second (FEV1) of at least 15% between bedtime and awakening in patients with clinical and physiologic evidence of asthma, which may include improvement in QoL.Methodology: The patient with Chronic Persistent Asthma, both sex, age >18 to 50 years of age and preferably patients with nocturnal exacerbations were included in the study. All patients were diagnosed on the basis of clinical history, physical examination, chest X-ray and pulmonary function tests, in accordance with the clinical criteria for the diagnosis by the GINA. The recruitment period was between March 2017 and August 2017 Shaheed Suhrawardy Medical College Hospital, Dhaka.Results: It was observed that 65(92.85%) was found exacerbation free night and 5(7.15%) patients were found exacerbation with sustained release Theophylline. There are significantly improved qualities of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up p<0.001 which was statistically significant. Spirometry test was gradually improved between 1st visit of FEV1 to 2nd, 3rd and 4th visit of FEV1, (p<0.001) that was statistically significant.Conclusion: Most of the patients were found exacerbation free night. There are significantly improved quality of life between 1st follow up to 2nd follow up, 3rd follow up and 4th follow up in Spirometry test. The value of FEV1 was gradually improve in the lst visit, 2nd, 3rd and 4th visit with sustained release Theophylline.J Shaheed Suhrawardy Med Coll, December 2017, Vol.9(2); 74-77


1998 ◽  
Vol 102 (6) ◽  
pp. 935-942 ◽  
Author(s):  
Robert A. Nathan ◽  
Jonathan A. Bernstein ◽  
Leonard Bielory ◽  
Catherine M. Bonuccelli ◽  
William J. Calhoun ◽  
...  

2015 ◽  
Vol 46 (3) ◽  
pp. 680-687 ◽  
Author(s):  
Brian D. Stucky ◽  
Cathy D. Sherbourne ◽  
Maria Orlando Edelen ◽  
Nicole K. Eberhart

This study identifies the unique contributions of asthma severity, symptoms, control and generic measures of quality of life (QoL) to asthma-specific QoL, as measured by the 12-item RAND Negative Impact of Asthma on Quality of Life scale (RAND-IAQL-12).Using a sample of 2032 adults with asthma, we conducted multiple regression analyses that sequentially examined hypothesised predictors of asthma-specific QoL. The change in variance accounted for and total unique variance accounted for is calculated as hypothesised predictors are added in each step.Our results indicate that asthma severity and asthma symptoms are strong predictors of asthma-specific QoL only when not controlling for aspects of asthma control. In regression models that include other aspects of asthma control, the contributions of both asthma symptoms and severity were substantially reduced, with asthma control and aspects of QoL related to social roles and activities emerging as the strongest predictors of asthma-specific QoL.These findings suggest that researchers measuring the impact of asthma on QoL should also consider the importance of asthma control as measured by the RAND Asthma Control Measure (RAND-ACM) and generic QoL scales that measure aspects of daily life that are uniquely affected by asthma.


2001 ◽  
Vol 7 (4) ◽  
pp. 281-286 ◽  
Author(s):  
Michael J. Romano ◽  
Jamie Hernandez ◽  
Allyson Gaylor ◽  
Shelly Howard ◽  
Retta Knox

Author(s):  
SA Uriarte ◽  
H Grönlund ◽  
A Wintersand ◽  
J Bronge ◽  
J Sastre

Objective: We aimed to evaluate the efficacy of and immunologic changes caused by subcutaneous immunotherapy (SCIT) in patients with allergy to cat and dog. Methods: Patients presenting rhinitis and/or asthma with allergy to cat or dog from a previous safety study were included. All had specific IgE to cat and/or dog. Using an infusion pump (IP), SCIT maintenance dose was administered over one 4-hour session, followed by monthly administration over 6 months. Data were gathered on clinical outcomes, pulmonary function, FeNO, rhinitis and asthma symptoms, quality of life (QoL), asthma control test (ACT), and symptom visual analog scale (VAS) at baseline and then at 1, 3, and 6 months. Specific IgE and IgG antibody responses to different cat and dog allergens were determined. Results: Sixty-one patients having a mean age of 35.6 ± 9.7 years were included, 40 of whom underwent cat SCIT. A significant improvement was observed in rhinitis and asthma symptoms and in QoL, use of medication, VAS, and ACT at 1 month; these improvements persisted at month 6. Clinical improvement with cat extract was significantly higher than with dog. An increase of >0.9 in ESPRINT-15 health-related quality of life in allergic rhinitis) was observed in 49.09% of patients, and 58.18% showed an increase of >0.5 in AQLQ(asthma quality of life questionnaire), at month 6, both differences indicating the minimal important difference. A significant increase was observed in specific IgG and IgE to different allergens at 3 and/or 6 months. Conclusions: Ultrarush SCIT with cat and dog extracts has substantial clinical value in many patients.


2010 ◽  
Vol 47 (2) ◽  
pp. 170-177 ◽  
Author(s):  
Michael Seid ◽  
Christine A. Limbers ◽  
Kimberly A. Driscoll ◽  
Lisa A. Opipari-Arrigan ◽  
Leticia Reyes Gelhard ◽  
...  

2007 ◽  
Vol &NA; ◽  
pp. S249
Author(s):  
Kamelija Busljetic ◽  
Tatjana Caparoska ◽  
Biserka Kaeva ◽  
Sava Pejkovska ◽  
Kamelija Busljetic

Sign in / Sign up

Export Citation Format

Share Document